# Brent Lavin

Brent Lavin is a medtech product and commercial-strategy adviser and the founder of Ironwood Medtech Partners. Lavin helps early-stage medtech companies build commercial logic into product development and connect clinical, technical, regulatory, and business decisions.

- Profile: https://b2binfluencer.marketing/creators/brent-lavin/
- LinkedIn: https://www.linkedin.com/in/brent-lavin
- LinkedIn followers: 2,754
- Topics: product-management
- Based on 13 dated posts, latest 2026-09-29

## Summary

Brent Lavin is most useful for medtech product and commercial strategy that connects clinical, technical, regulatory, and business decisions.

- Best for: Early-stage medtech company wanting commercial logic in its product-development pipeline.
- Not for: A consumer brand wanting a high-reach creator endorsement for a lifestyle product.
- Check first: Confirm scope, terms, and audience evidence before contacting them.

### Takeaways

- The business case needs one accountable owner.
- Physicians can have valid but conflicting needs while one product must be chosen.
- Added product options can increase development and regulatory complexity.

## Main ideas

- **The business case needs one accountable owner**: Lavin treats the business case as product management’s common language, where engineering, clinical, regulatory, and commercial choices meet. The problem, they say, is that no single function owns the whole case. Specialized teams optimize within their own lanes, and the program drifts one reasonable decision at a time until the approved product no longer matches the business originally imagined. Guarding the business case means weighing those trade-offs through the customer’s lens and making their consequences clear to the business.
- **Turn many physician voices into one product**: Lavin describes physicians as holding strong, earned beliefs about how a procedure should be done, shaped by training, health system, and local economics. The product owner’s hardest job is to separate signal from noise and synthesize diverse input into one set of product attributes. They call that synthesis part science—deciding which needs are universal, segment-specific, individual preference, or loud but commercially shallow—and part art: having the conviction to converge and say what is being built, for whom, and why.
- **Coordination is the bottleneck, not technology**: Lavin’s public positioning centers on cross-functional translation. Responding to a Harvard Business Review article on bridging, they summarize three bridger activities: curate the right partners, translate across different languages and priorities, and integrate disparate efforts into coordinated execution. They say their medtech career has involved doing exactly that among specialized teams, global partners, and acquisitions—translating between physicians, engineers, regulators, payers, hospital procurement, and investors. Their conclusion: technology is rarely the problem; coordination is.
- **Set kill criteria before sunk cost decides**: Lavin tells a cautionary story about a product that was approved and then went nowhere in the market. The design and manufacturing were genuinely new, but market conditions shifted during development. Reimbursement fell faster than usual, competitors started fighting on price, and supply-chain disruption raised costs. The team kept using a launch plan built on a pricing assumption that had stopped being true two years earlier, while sunk costs made stopping unattractive. Lavin asks what the kill criteria are and who is allowed to call it.
- **Build commercial logic into early-stage innovation**: Lavin’s priorities have shifted alongside changes in medtech. In a career reflection, they describe leaving GE and family in Milwaukee for a smaller, more nimble company in Phoenix, later acquired, and then watching the industry shift toward larger strategics, heavier regulation, more employed physicians, and reimbursement pressure. They argue that large strategics are pursuing less organic innovation, new product development is more complex, and funding is harder. Ironwood Medtech Partners is meant to fill that gap by helping early-stage companies build commercial logic into innovation and turn technologies into viable businesses.

## Work to read

- [What does it mean to guard the business case?](https://www.linkedin.com/posts/brent-lavin_what-does-it-mean-to-guard-the-business-case-activity-7455243247322562560-1jKb)
- [Many voices in, one product out: physician input and product synthesis](https://www.linkedin.com/posts/brent-lavin_ive-talked-with-thousands-of-physicians-activity-7458138574501105665-Hjvm)
- [We got the product approved and then it went nowhere](https://www.linkedin.com/posts/brent-lavin_we-got-the-product-approvedand-then-it-activity-7498008283538968576-_LLX)
- [Bridging and why great innovations fail to scale](https://www.linkedin.com/posts/brent-lavin_why-great-innovations-fail-to-scale-activity-7432422119604539393-MzD1)
- [When you design for everybody, you end up designing for nobody](https://www.linkedin.com/posts/brent-lavin_when-you-design-for-everybody-you-end-up-activity-7439305748364369920-OAn3)
- [Fifteen years in Arizona and the move to Ironwood Medtech Partners](https://www.linkedin.com/posts/brent-lavin_today-marks-15-years-since-we-moved-to-az-activity-7428811584933888000--aZj)

## Brand relationships

- **Ironwood Medtech Partners** (owned_business)
- **CR Bard** (employment)
- **Becton Dickinson (BD)** (employment)
- **GE** (employment)
- **Harvard Business Review** (mention)
- **State of Medtech** (mention)

## Partnerships

Lavin describes Ironwood Medtech Partners as a commercial-strategy and product-management practice that takes on an ongoing role inside a company's innovation program, rather than delivering a one-off review. The work involves owning the integrated business case across engineering, regulatory, clinical, and commercial decisions, and connecting specialized teams, global partners, and acquisitions so a product concept becomes a commercial business. Ask for official partnership or engagement pages, pricing, and contact routes; these are not shown in their posts.

## Alternatives

- Michael Belkin JD, MSHA, FACHE, CMPE: Choose Michael Belkin when the medtech buyer's decision is really about clinician supply, staffing, burnout, or workforce planning inside a health system—not building commercial logic into a device pipeline. The posts argue that healthcare organizations should forecast demand by service line, track retirement and attrition, and build clinician pipelines before coverage gaps become urgent. They also connect physician burnout to turnover, specialty instability, and flexible staffing models. If the buyer needs to assess how a commercial plan depends on physician availability, retention, or care-delivery capacity, Belkin's posts speak directly to that decision.
- Ahmed Omar: Choose Ahmed Omar when the campaign decision is about deploying healthcare AI in a health system and proving financial return, administrative relief, or prior-authorization improvement. The posts frame the choice between AI that increases health-system revenue and AI that saves society money. They break down prior authorization as both a cost and morale problem, citing an employee-cost comparison and focusing on removing administrative work from clinicians. For buyers deciding which AI investment a hospital will adopt and how to make the ROI legible, these posts are closer to the decision than Lavin's product-business-case posts.
- Bilal Bham: Choose Bilal Bham when the buyer's task shifts from device commercialization to pharmaceutical, radiopharma, or psychedelic-medicine development and market access. The posts analyze clinical replication, treatment-center capacity, monitoring and reimbursement requirements, isotope supply and manufacturing strategy, and the need for regulatory, CMC, clinical, and access narratives to describe the same source of value. Companies weighing an investment or access strategy in those areas will find these posts closer to their decision than a device-focused product-management profile.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/